Trial · NCT02357810
Results by group37
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 37
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression Free Survival at 12 Weeks for Patients With Soft Tissue Sarcoma (STS) Treated With Pazopanib and Oral Topotecan | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 57.5 | percentage of patients progression free | ||
| Overall Response Rate (ORR) for Patients With Soft Tissue Sarcoma (STS) Treated With Combination Pazopanib and Topotecan. | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 7 | Participants | ||
| Clinical Benefit Rate (CBR) for Patients With Soft Tissue Sarcoma (STS) Treated With Combination Pazopanib and Topotecan. | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 66 | Participants | ||
| Overall Survival (OS) for Patients With Soft Tissue Sarcoma (STS) Treated With Combination Pazopanib and Topotecan. | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 10.94 | 95% Confidence Interval 9.30 to 18.73 | months | |
| Number of Patients With Significant Adverse Events, Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | Anemia | 32 | patients | |
| Number of Patients With Significant Adverse Events, Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | Platelet count decreased | 61 | patients | |
| Number of Patients With Significant Adverse Events, Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | Decreased neutrophil count | 80 | patients | |
| Number of Patients With Significant Adverse Events, Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | Hypertension | 35 | patients | |
| Number of Patients With Significant Adverse Events, Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | Fatigue | 13 | patients | |
| Number of Patients With Significant Adverse Events, Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | Nausea | 5 | patients | |
| Number of Patients With Significant Adverse Events, Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | Hyperglycemia | 6 | patients | |
| Number of Patients With Significant Adverse Events, Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | Diarrhea | 13 | patients | |
| Number of Patients With Significant Adverse Events, Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | Vomiting | 11 | patients | |
| Number of Patients With Significant Adverse Events, Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | Anorexia | 3 | patients | |
| Number of Patients With Significant Adverse Events, Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | Alkaline phosphatase increase | 6 | patients | |
| Number of Patients With Significant Adverse Events, Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | Hyponatremia | 17 | patients | |
| Number of Patients With Significant Adverse Events, Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | Hypocalcemia | 1 | patients | |
| Number of Patients With Significant Adverse Events, Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | Aspartate aminotransferase increased | 6 | patients | |
| Number of Patients With Significant Adverse Events, Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | Prolonged PTT | 3 | patients | |
| Number of Patients With Significant Adverse Events, Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | GGT increase | 7 | patients |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02357810/results